Pharma Awaits Market Impact Of Added FDA Bill Safety Proposals, IMS Says
Executive Summary
FDA's safety assessments may serve as the wildcard for how the pharmaceutical market will play out in 2008, IMS says, as the agency evaluates safety priorities and implements additional postmarket review strategies authorized by the FDA Amendments Act